JP2024509282A5 - - Google Patents

Info

Publication number
JP2024509282A5
JP2024509282A5 JP2023555333A JP2023555333A JP2024509282A5 JP 2024509282 A5 JP2024509282 A5 JP 2024509282A5 JP 2023555333 A JP2023555333 A JP 2023555333A JP 2023555333 A JP2023555333 A JP 2023555333A JP 2024509282 A5 JP2024509282 A5 JP 2024509282A5
Authority
JP
Japan
Prior art keywords
groups
group
substituted
alkyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/019658 external-priority patent/WO2022192478A1/en
Publication of JP2024509282A publication Critical patent/JP2024509282A/ja
Publication of JP2024509282A5 publication Critical patent/JP2024509282A5/ja
Pending legal-status Critical Current

Links

JP2023555333A 2021-03-10 2022-03-10 ガラクトース欠損免疫グロブリンの二官能性分解剤 Pending JP2024509282A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163159383P 2021-03-10 2021-03-10
US63/159,383 2021-03-10
PCT/US2022/019658 WO2022192478A1 (en) 2021-03-10 2022-03-10 Bifunctional degraders of galactose-deficient immunoglobulins

Publications (2)

Publication Number Publication Date
JP2024509282A JP2024509282A (ja) 2024-02-29
JP2024509282A5 true JP2024509282A5 (cg-RX-API-DMAC10.html) 2025-03-19

Family

ID=83227063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555333A Pending JP2024509282A (ja) 2021-03-10 2022-03-10 ガラクトース欠損免疫グロブリンの二官能性分解剤

Country Status (11)

Country Link
US (2) US20240309114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4304579A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024509282A (cg-RX-API-DMAC10.html)
KR (1) KR20230154900A (cg-RX-API-DMAC10.html)
CN (1) CN116997337A (cg-RX-API-DMAC10.html)
AU (1) AU2022232620A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023017702A2 (cg-RX-API-DMAC10.html)
CA (1) CA3211335A1 (cg-RX-API-DMAC10.html)
IL (1) IL305665A (cg-RX-API-DMAC10.html)
MX (1) MX2023010424A (cg-RX-API-DMAC10.html)
WO (1) WO2022192478A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12023553152A1 (en) * 2021-05-17 2024-03-11 Biohaven Therapeutics Ltd Compositions including conjugated therapy enhancers
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
CN121038815A (zh) * 2023-04-29 2025-11-28 拜奥海芬治疗学有限公司 半乳糖缺陷型免疫球蛋白的双功能降解剂
WO2026083257A1 (en) 2024-10-14 2026-04-23 Biohaven Therapeutics Ltd. Antigen-specific degraders of immunoglobulin a and their uses
WO2026120177A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Novel long-acting degrader conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440191B2 (en) * 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
DK2991683T3 (da) * 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
CA2946064C (en) * 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
RU2696490C2 (ru) * 2014-05-19 2019-08-02 Пфайзер Инк. Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR
CA3134610A1 (en) * 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins

Similar Documents

Publication Publication Date Title
CN102227442B (zh) Sars冠状病毒的细胞毒性t细胞表位肽及其用途
JP5537431B2 (ja) ウイルス融合のインヒビターのコレステロール誘導体
TWI839055B (zh) 聚乙二醇化的藥物-連接劑及其中間體
SA518391996B1 (ar) نظائر عامل النمو الجلدي شبيه مجال أ ببدائل حمض دهني
JP7089062B2 (ja) 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Bclファミリーアンタゴニストであるホスホリジン
CN117915956A (zh) M6pr细胞表面受体结合化合物和缀合物
JP2024509282A (ja) ガラクトース欠損免疫グロブリンの二官能性分解剤
Zhuang et al. Robo4 vaccines induce antibodies that retard tumor growth
CA3132994A1 (en) Tlr4 and tlr7 ligand formulations as vaccine adjuvants
CN114917358A (zh) 用于治疗癌症和炎症性疾病的偶联物和前药
KR20220097921A (ko) 인터루킨-22의 치료 유도체
JP2025186263A (ja) Epi-x4系ペプチドおよびその誘導体
CN102232083B (zh) 禽流感疫苗
CN117355340A (zh) 缀合物及其制备方法和用途
ES2322253T3 (es) Utilizacion de mezclas de lipopeptidos para la fabricacion de vacunas.
JPH04506666A (ja) ワクチンアジュバントとしてのlfa―3
WO2012050193A1 (ja) エボラウイルスリポソームワクチン
JP5930967B2 (ja) C型肝炎ウイルスリポソームワクチン
WO2018129618A1 (en) An agent for promoting angiogenesis and methods and uses thereof
CN118019547A (zh) 热稳定脂质纳米粒子及其使用方法
CA3171449C (en) Coronavirus therapeutics and treatment methods
CA3171449A1 (en) Coronavirus therapeutics and treatment methods
AU2009344150B2 (en) Immunogenic composition and uses thereof
HK1236815A1 (en) Conjugates and prodrugs for treating of cancer and inflammatory diseases